Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NMR trial models: experiences with the colicin immunity protein Im7 and the p85 alpha C-terminal SH2-peptide complex
Autore:
Pauptit, RA; Dennis, CA; Derbyshire, DJ; Breeze, AL; Weston, SA; Roswell, S; Murshudov, GN;
Indirizzi:
AstraZeneca, Macclesfield SK10 4TG, Cheshire, England AstraZeneca Macclesfield Cheshire England SK10 4TG 4TG, Cheshire, England Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England Univ Leeds Leeds W Yorkshire England LS2 9JT S2 9JT, W Yorkshire, England Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Dept Haematol, Cambridge CB2 2XY, England Univ Cambridge Cambridge England CB2 2XY tol, Cambridge CB2 2XY, England Univ York, Dept Chem, York YO10 5DD, N Yorkshire, England Univ York York N Yorkshire England YO10 5DD O10 5DD, N Yorkshire, England
Titolo Testata:
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
, volume: 57, anno: 2001,
parte:, 10
pagine: 1397 - 1404
SICI:
0907-4449(200110)57:<1397:NTMEWT>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
SH2 DOMAIN; CRYSTAL-STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR REPLACEMENT; SUBUNIT; REFINEMENT; COGNATE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Pauptit, RA AstraZeneca, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England AstraZeneca Alderley Pk Macclesfield Cheshire England SK10 4TG
Citazione:
R.A. Pauptit et al., "NMR trial models: experiences with the colicin immunity protein Im7 and the p85 alpha C-terminal SH2-peptide complex", ACT CRYST D, 57, 2001, pp. 1397-1404

Abstract

Two cases of successful molecular replacement using NMR trial models are presented. One is the crystal structure of the Escherichia coli colicin immunity protein Im7; the other is a heretofore unreported crystal structure ofa specific PDGF receptor-derived peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of human phosphatidylinositol 3-OH kinase. In both cases, molecular replacement was non-trivial. Success was achieved using trial models that consisted of an ensemble of NMR structures from which the more flexible portions had been excized. Use of maximum-likelihood refinement proved critical to be able to refine the poor starting models. The challenges typical of the use of NMR trial models in molecular replacement are discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:02:21